Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bausch Health Companies Inc T.BHC

Alternate Symbol(s):  BHC

Healthcare
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.


TSX:BHC - Post by User

Bausch Health Companies Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by PressReleaseon Oct 03, 2022 8:01am
56 Views
Post# 35001006

New Press Release - SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY

New Press Release - SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY
Centers for Medicare & Medicaid Services (CMS) Launch of New Code Coincides with Liver Awareness Month, a Time to Make Liver Health a National Health Care PriorityLAVAL, QC, Oct. 3, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology...read article.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities